Insmed (NASDAQ:INSM) Sees Strong Trading Volume - Should You Buy?

Insmed Incorporated (NASDAQ:INSM - Get Free Report) shares saw an uptick in trading volume on Friday . Approximately 10,333,584 shares were traded during trading, an increase of 352% from the previous session's volume of 2,285,543 shares.The stock last traded at $69.34 and had previously closed at $68.96.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on INSM shares. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. JPMorgan Chase & Co. boosted their target price on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Stifel Nicolaus reduced their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. HC Wainwright reiterated a "buy" rating and set a $90.00 price target on shares of Insmed in a research note on Tuesday, April 22nd. Finally, UBS Group raised their price objective on Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Insmed Trading Up 0.8 %

The business's 50-day simple moving average is $73.86 and its 200-day simple moving average is $73.52. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $13.09 billion, a PE ratio of -12.88 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Activity

In other Insmed news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the sale, the chief financial officer now directly owns 118,863 shares of the company's stock, valued at approximately $9,545,887.53. The trade was a 13.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00. Following the completion of the transaction, the chief executive officer now directly owns 379,534 shares of the company's stock, valued at approximately $29,580,879.96. The trade was a 4.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 471,797 shares of company stock valued at $37,621,239. Insiders own 3.00% of the company's stock.

Institutional Trading of Insmed

Large investors have recently bought and sold shares of the stock. Elequin Capital LP bought a new stake in shares of Insmed in the 4th quarter worth about $28,000. Steward Partners Investment Advisory LLC increased its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Insmed in the first quarter valued at approximately $49,000. V Square Quantitative Management LLC increased its holdings in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares in the last quarter. Finally, Spire Wealth Management acquired a new position in Insmed in the fourth quarter worth $47,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.